Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15319971 | 0.79 | LMNA (0.39) | ALDH1A1MEN1KMT2ALMNATSHR | |
| SCHEMBL16609900 | 0.77 | MEN1 (0.47) | TLR4ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL15427994 | 0.76 | MEN1 (0.49) | TLR4ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20988214 | 0.76 | MEN1 (0.46) | TLR4ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL23228558 | 0.76 | MEN1 (0.46) | TLR4ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL14345645 | 0.75 | MEN1 (0.59) | ALDH1A1MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL10813366 | 0.74 | MEN1 (0.58) | ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL6583721 | 0.74 | ALDH1A1 (0.40) | TLR4ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL940891 | 0.73 | KMT2A (0.47) | TLR4ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL9829971 | 0.73 | MAPT (0.41) | TLR4ALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093623-B2 | Cyclic amides as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2018-10-09 | — | — | US | disclosed |
| EP-2834221-B1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-05-25 | — | — | EP | disclosed |
| EP-2834221-B1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-20150031670-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-29 | — | — | US | disclosed |
| US-20150031670-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-29 | — | — | US | disclosed |
| US-20150031670-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-29 | — | — | US | disclosed |
| WO-2013149704-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093623-B2 | Cyclic amides as MetAP-2 inhibitors | METAP2, METAP1, LNPEP | TLR4 4598/4885ALDH1A1 3706/4885MEN1 100/4885 |
| US-20150031670-A1 | CYCLIC AMIDES AS METAP-2 INHIBITORS | METAP2, METAP1, ENPEP | TLR4 4532/4885ALDH1A1 3225/4885MEN1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.